TOVX Earnings Theriva Biologics, Inc.
Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Latest filing
Annual results
EPS
Net income
ROE
Quarterly results
EPS
Revenue
Net income
Reported EPS history
1–51 of 51
| Q2 2026 | 2026-06-30 | -0.07 | 2026-08-11 | 10-Q |
| Q1 2026 | 2026-03-31 | -0.05 | 2026-05-05 | 10-Q |
| Q4 2025 (derived) | 2025-12-31 | 1.85 | 2026-03-12 | 10-K |
| FY 2025 | 2025-12-31 | -2.08 | 2026-03-12 | 10-K |
| Q3 2025 | 2025-09-30 | -0.45 | 2025-11-12 | 10-Q |
| Q2 2025 | 2025-06-30 | -1.93 | 2025-08-11 | 10-Q |
| Q1 2025 | 2025-03-31 | -1.55 | 2025-05-14 | 10-Q |
| Q4 2024 (derived) | 2024-12-31 | 6.03 | 2025-03-06 | 10-K |
| FY 2024 | 2024-12-31 | -19.03 | 2025-03-06 | 10-K |
| Q3 2024 | 2024-09-30 | -6.81 | 2024-11-12 | 10-Q |
| Q2 2024 | 2024-06-30 | -10.72 | 2024-08-13 | 10-Q |
| Q1 2024 | 2024-03-31 | -7.53 | 2024-05-07 | 10-Q |
| Q4 2023 (derived) | 2023-12-31 | -7.63 | 2024-03-25 | 10-K |
| FY 2023 | 2023-12-31 | -28.48 | 2024-03-25 | 10-K |
| Q3 2023 | 2023-09-30 | -4.85 | 2023-11-13 | 10-Q |
| Q2 2023 | 2023-06-30 | -8.50 | 2023-08-08 | 10-Q |
| Q1 2023 | 2023-03-31 | -7.50 | 2023-05-11 | 10-Q |
| Q4 2022 (derived) | 2022-12-31 | -10.50 | 2023-03-30 | 10-K |
| FY 2022 | 2022-12-31 | -32.75 | 2023-03-30 | 10-K |
| Q3 2022 | 2022-09-30 | -7.50 | 2022-11-10 | 10-Q |
| Q2 2022 | 2022-06-30 | -7.00 | 2022-08-11 | 10-Q |
| Q1 2022 | 2022-03-31 | -7.75 | 2022-05-16 | 10-Q |
| Q4 2021 (derived) | 2021-12-31 | -32.00 | 2022-03-16 | 10-K |
| FY 2021 | 2021-12-31 | -47.50 | 2022-03-16 | 10-K |
| Q3 2021 | 2021-09-30 | -6.25 | 2021-11-03 | 10-Q |
| Q2 2021 | 2021-06-30 | -6.00 | — | — |
| Q1 2021 | 2021-03-31 | -3.25 | — | — |
| FY 2020 | 2020-12-31 | -16.50 | — | — |
| Q3 2020 | 2020-09-30 | -3.50 | — | — |
| Q3 2019 | 2019-09-30 | -7.75 | 2019-11-04 | 10-Q |
| Q2 2019 | 2019-06-30 | -5.75 | 2019-08-08 | 10-Q |
| Q1 2019 | 2019-03-31 | -6.25 | 2019-05-08 | 10-Q |
| Q4 2018 | 2018-12-31 | -28.00 | 2019-02-27 | 10-K |
| Q3 2018 | 2018-09-30 | -23.25 | 2018-11-08 | 10-Q |
| Q2 2018 | 2018-06-30 | -29.00 | 2018-08-08 | 10-Q |
| Q1 2018 | 2018-03-31 | -16.25 | 2018-05-08 | 10-Q |
| Q4 2017 | 2017-12-31 | 19.00 | 2018-02-22 | 10-K |
| Q3 2017 | 2017-09-30 | -122.50 | 2017-11-01 | 10-Q |
| Q2 2017 | 2017-06-30 | -26.25 | 2017-08-03 | 10-Q |
| Q1 2017 | 2017-03-31 | -17.50 | 2017-05-04 | 10-Q |
| Q4 2016 | 2016-12-31 | -0.50 | 2017-03-02 | 10-K |
| Q3 2016 | 2016-09-30 | -2.25 | 2016-11-01 | 10-Q |
| Q2 2016 | 2016-06-30 | -2.50 | 2016-08-03 | 10-Q |
| Q1 2016 | 2016-03-31 | -3.00 | — | — |
| Q4 2015 | 2015-12-31 | -3.00 | 2016-03-10 | 10-K |
| Q3 2015 | 2015-09-30 | -3.00 | 2015-11-05 | 10-Q |
| Q2 2015 | 2015-06-30 | -4.75 | — | — |
| Q1 2015 | 2015-03-31 | -4.25 | — | — |
| Q3 2014 | 2014-09-30 | -2.00 | — | — |
| Q2 2011 | 2011-06-30 | -1.50 | 2011-08-15 | 10-Q |
| Q2 2010 | 2010-06-30 | 1.25 | — | — |
Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Q4 EPS marked "derived" is computed as the fiscal-year EPS minus Q1–Q3 (10-Ks report only the annual figure); EPS is not strictly additive across quarters, so it can differ by a cent or two from the issuer's own Q4. A period with no "Reported" date is known only from a later filing's prior-year comparative. Informational only — not financial advice.